United States — United States Securities and Exchange Commission & MiNK Therapeutics

United States — United States Securities and Exchange Commission: The United States — United States Securities and Exchange Commission is the regulatory body under whose rules MiNK Therapeutics filed a Form 8-K and whose regulations are cited in the class action lawsuits.

MiNK Therapeutics: MiNK Therapeutics is the primary defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about the safety and commercial viability of its drug candidate, DCCR. The company's stock price has significantly declined following reports of safety concerns, a patient death, and disruptions in DCCR's launch.